Literature DB >> 34458913

Potential test-negative design study bias in outbreak settings: application to Ebola vaccination in Democratic Republic of Congo.

Carl A B Pearson1,2, W John Edmunds1, Thomas J Hladish3, Rosalind M Eggo1.   

Abstract

BACKGROUND: Infectious disease outbreaks present unique challenges to study designs for vaccine evaluation. Test-negative design (TND) studies have previously been used to estimate vaccine effectiveness and have been proposed for Ebola virus disease (EVD) vaccines. However, there are key differences in how cases and controls are recruited during outbreaks and pandemics of novel pathogens, whcih have implications for the reliability of effectiveness estimates using this design.
METHODS: We use a modelling approach to quantify TND bias for a prophylactic vaccine under varying study and epidemiological scenarios. Our model accounts for heterogeneity in vaccine distribution and for two potential routes to testing and recruitment into the study: self-reporting and contact-tracing. We derive conventional and hybrid TND estimators for this model and suggest ways to translate public health response data into the parameters of the model.
RESULTS: Using a conventional TND study, our model finds biases in vaccine effectiveness estimates. Bias arises due to differential recruitment from self-reporting and contact-tracing, and due to clustering of vaccination. We estimate the degree of bias when recruitment route is not available, and propose a study design to eliminate the bias if recruitment route is recorded.
CONCLUSIONS: Hybrid TND studies can resolve the design bias with conventional TND studies applied to outbreak and pandemic response testing data, if those efforts collect individuals' routes to testing. Without route to testing, other epidemiological data will be required to estimate the magnitude of potential bias in a conventional TND study. Since these studies may need to be conducted retrospectively, public health responses should obtain these data, and generic protocols for outbreak and pandemic response studies should emphasize the need to record routes to testing.
© The Author(s) 2021. Published by Oxford University Press on behalf of the International Epidemiological Association.

Entities:  

Keywords:  DRC; Ebola; Test-negative design; mathematical modelling; outbreak response

Mesh:

Year:  2022        PMID: 34458913      PMCID: PMC8855996          DOI: 10.1093/ije/dyab172

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  33 in total

1.  Plan to use second Ebola vaccine sparks debate.

Authors:  Kai Kupferschmidt
Journal:  Science       Date:  2019-06-28       Impact factor: 47.728

2.  RE: "INVITED COMMENTARY: BEWARE THE TEST-NEGATIVE DESIGN".

Authors:  Jill M Ferdinands; Ivo M Foppa; Alicia M Fry; Brendan L Flannery; Edward A Belongia; Michael L Jackson
Journal:  Am J Epidemiol       Date:  2017-04-01       Impact factor: 4.897

3.  Ethical considerations for vaccination programmes in acute humanitarian emergencies.

Authors:  Keymanthri Moodley; Kate Hardie; Michael J Selgelid; Ronald J Waldman; Peter Strebel; Helen Rees; David N Durrheim
Journal:  Bull World Health Organ       Date:  2013-02-07       Impact factor: 9.408

4.  The case test-negative design for studies of the effectiveness of influenza vaccine.

Authors:  Ivo M Foppa; Michael Haber; Jill M Ferdinands; David K Shay
Journal:  Vaccine       Date:  2013-04-23       Impact factor: 3.641

Review 5.  Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review.

Authors:  Sheena G Sullivan; Shuo Feng; Benjamin J Cowling
Journal:  Expert Rev Vaccines       Date:  2014-10-28       Impact factor: 5.217

6.  Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness.

Authors:  Evan W Orenstein; Gaston De Serres; Michael J Haber; David K Shay; Carolyn B Bridges; Paul Gargiullo; Walter A Orenstein
Journal:  Int J Epidemiol       Date:  2007-04-02       Impact factor: 7.196

7.  A comparison of the test-negative and traditional case-control study designs with respect to the bias of estimates of rotavirus vaccine effectiveness.

Authors:  Michael Haber; Benjamin A Lopman; Jacqueline E Tate; Meng Shi; Umesh D Parashar
Journal:  Vaccine       Date:  2018-07-03       Impact factor: 3.641

Review 8.  The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts.

Authors:  Massinissa Si Mehand; Farah Al-Shorbaji; Piers Millett; Bernadette Murgue
Journal:  Antiviral Res       Date:  2018-09-24       Impact factor: 5.970

9.  Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017-18: a test-negative case-control study.

Authors:  Yu Li; Yonghong Zhou; Yibing Cheng; Peng Wu; Chongchen Zhou; Peng Cui; Chunlan Song; Lu Liang; Fang Wang; Qi Qiu; Chun Guo; Mengyao Zeng; Lu Long; Benjamin J Cowling; Hongjie Yu
Journal:  Lancet Child Adolesc Health       Date:  2019-07-30

10.  Bias due to differential and non-differential disease- and exposure misclassification in studies of vaccine effectiveness.

Authors:  Tom De Smedt; Elizabeth Merrall; Denis Macina; Silvia Perez-Vilar; Nick Andrews; Kaatje Bollaerts
Journal:  PLoS One       Date:  2018-06-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.